for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

79.62USD

Change

2.61(+3.39%)

Volume

1,245,823

Today's Range

77.26

 - 

79.80

52 Week Range

70.90

 - 

91.40

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
77.01
Open
77.26
Volume
1,245,823
3M AVG Volume
288.03
Today's High
79.80
Today's Low
77.26
52 Week High
91.40
52 Week Low
70.90
Shares Out (MIL)
2,525.94
Market Cap (MIL)
194,522.90
Forward P/E
13.34
Dividend (Yield %)
3.58

Next Event

Q4 2021 Merck & Co Inc Earnings Call

Latest Developments

More

Merck And Ridgeback's Molnupiravir, Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval For Emergency In Japan

Merck And Ridgeback’S Molnupiravir Receives U.S. FDA Emergency Use Authorization For The Treatment Of High-Risk Adults With Mild To Moderate Covid-19

FDA Says Molnupiravir Is Not Recommended For Use During Pregnancy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Executive Chairman of the Board

Robert M. Davis

President, Chief Executive Officer, Director

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

2.18 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

48.7K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

5.773
Price To Earnings (TTM)
30.42
Price To Sales (TTM)
4.08
Price To Book (MRQ)
5.43
Price To Cash Flow (TTM)
20.00
Total Debt To Equity (MRQ)
73.87
LT Debt To Equity (MRQ)
64.00
Return on Investment (TTM)
9.27
Return on Equity (TTM)
7.03

Latest News

Latest News

Factbox-Latest on the worldwide spread of the coronavirus

Britain and Israel are overhauling their COVID-19 testing policies as governments seek to ease the burden on laboratories and struggle with tight supplies of kits amid soaring infection rates fuelled by the Omicron variant.

India says safety concerns restricting use of Merck COVID pill

India has not added Merck's COVID-19 pill to its national treatment protocol for the disease due to known safety concerns that have restricted its use elsewhere, a senior health official told a media briefing on Wednesday.

South Korea agrees to buy additional Pfizer COVID-19 pills

South Korea signed an agreement to buy additional courses of Pfizer Inc's antiviral COVID-19 pill Paxlovid to cover 400,000 people, the Korea Disease Control and Prevention Agency (KDCA) said on Wednesday.

India health official says Merck COVID pill has 'major safety concerns'

India has not added Merck's COVID-19 pill in its national treatment protocol for the disease due to some "major safety concerns", a senior health official told a media briefing on Wednesday.

Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill

Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday.

Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill

Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday.

UPDATE 1-Belgium agrees to buy 10,000 courses each of Pfizer, Merck COVID-19 pills

Belgium has agreed to buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry told Reuters in an emailed statement on Monday.

Belgium to buy 10,000 courses each of Pfizer and Merck COVID-19 pills

Belgium will buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry said in an emailed statement.

Israel to offer fourth COVID vaccine shot to over 60s, medical staff

Prime Minister Naftali Bennett said on Sunday that Israel would offer a fourth dose of COVID-19 vaccine to people over 60 and to medical staff as it faces a surge in Omicron variant infections.

India boosts arsenal against COVID-19 with Merck pill, two more vaccines

India has approved Merck's COVID-19 pill and two more vaccines for emergency use as the world's second most populous country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant.

India committee recommends EUA for Merck's COVID-19 pill, two other vaccines - report

India's drug regulator expert committee recommended emergency use authorisation (EUA) for Merck & Co Inc's COVID-19 pill molnupiravir, and Serum Institute of India's covovax and Biological E's corbevax vaccines, the Economic Times reported on Tuesday.

BRIEF-Merck And Ridgeback's Molnupiravir, Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval For Emergency In Japan

* MERCK AND RIDGEBACK’S MOLNUPIRAVIR, AN INVESTIGATIONAL ORAL ANTIVIRAL COVID-19 TREATMENT, RECEIVES SPECIAL APPROVAL FOR EMERGENCY IN JAPAN

Japan health panel approves Merck's oral COVID-19 treatment

A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc, part of Prime Minister Fumio Kishida's plan to roll out new treatments by year-end as concerns rise about the Omicron variant.

Japan health panel approves Merck's oral COVID-19 treatment - NHK

Japanese regulators on Friday approved the COVID-19 antiviral pill developed by Merck & Co Inc , national broadcaster NHK reported.

U.S. authorizes Merck pill as second at-home COVID-19 treatment

The U.S. on Thursday authorized Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-19...

US STOCKS-Wall Street rises for third day as Omicron fears ease

* Indexes up: Dow 0.62%, S&P 0.73%, Nasdaq 0.99% (Updates with mid-afternoon trading)

Merck and Pfizer COVID-19 pills effective against Omicron -U.S. FDA official

Available data indicates that both Merck's and Pfizer's COVID-19 anti-viral treatments are effective against the Omicron variant of the coronavirus, a top U.S. Federal Drug Administration official said on Thursday.

U.S. FDA authorizes Merck's at-home antiviral COVID-19 pill

The U.S. Food and Drug Administration on Thursday authorized Merck & Co's antiviral pill for COVID-19, after giving the go-ahead to a similar treatment from Pfizer Inc. a day earlier.

Philippines approves Merck's COVID-19 pill for at-risk patients

The Philippines on Thursday approved emergency use of Merck & Co Inc's COVID-19 treatment pill for adult patients at risk of developing severe illness as it tries to boosts the country's arsenal of drugs to fight new variants.

France cancels order for Merck's COVID-19 antiviral drug

France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up